Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Cancer Gene Ther. 2012 Apr 20;19(7):443–450. doi: 10.1038/cgt.2012.14

Figure 1. Characterization of recombinant VSV-IFN in vitro.

Figure 1

5TGM1 cells were infected at with a Vesicular stomatitis virus (VSV) coding for GFP, murine IFNβ (VSV-mIFN) or human IFNβ (VSV-hIFN) at multiplicity of infection (MOI) 3.0. Cells were analyzed at specific time points to measure (A) viral replication by measuring viral titer in supernatant of infected cells (B) Viral murine IFNβ expression by ELISA analysis of cell supernatant, and (C) cell viability by MTT assay. (D) VSV-IFN specificity was evaluated by comparing viability of 5TGM1 versus SR4987 murine bone marrow stromal cells at 48h following mock infection or infection with VSV-mIFNβ or VSV-GFP (MOI 3.0).